NCT05988034View on ClinicalTrials.gov

A Study to Assess the Effect of Avacopan at Therapeutic and Supratherapeutic Doses on the QT/QTc Interval in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

November 8, 2019

Primary Completion Date

January 22, 2020

Study Completion Date

March 31, 2020

Conditions
Electrocardiography
Interventions
DRUG

Avacopan

Administered orally.

DRUG

Moxifloxacin

Administered orally.

DRUG

Placebo for avacopan

Administered orally.

DRUG

Placebo for moxifloxacin

Administered orally.

Trial Locations (1)

85283

Celerion, Tempe

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY